Financial Comparison: Edge Therapeutics (EDGE) vs. Its Peers

Edge Therapeutics (NASDAQ: EDGE) is one of 289 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its rivals? We will compare Edge Therapeutics to similar companies based on the strength of its profitability, valuation, dividends, earnings, analyst recommendations, risk and institutional ownership.

Profitability

This table compares Edge Therapeutics and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Edge Therapeutics N/A -56.88% -43.74%
Edge Therapeutics Competitors -5,322.24% -84.37% -35.66%

Insider & Institutional Ownership

50.3% of Edge Therapeutics shares are held by institutional investors. Comparatively, 49.8% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 36.2% of Edge Therapeutics shares are held by company insiders. Comparatively, 16.8% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Edge Therapeutics and its rivals gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Edge Therapeutics N/A -$38.82 million -7.05
Edge Therapeutics Competitors $290.27 million $35.99 million 56.11

Edge Therapeutics’ rivals have higher revenue and earnings than Edge Therapeutics. Edge Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Edge Therapeutics and its rivals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Edge Therapeutics 0 1 1 0 2.50
Edge Therapeutics Competitors 954 3404 11910 239 2.69

Edge Therapeutics currently has a consensus target price of $25.50, suggesting a potential upside of 131.82%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 40.53%. Given Edge Therapeutics’ higher possible upside, equities analysts clearly believe Edge Therapeutics is more favorable than its rivals.

Summary

Edge Therapeutics rivals beat Edge Therapeutics on 7 of the 12 factors compared.

About Edge Therapeutics

Edge Therapeutics, Inc. is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening critical care conditions. The Company’s initial product candidates target rare, acute, life-threatening neurological and other conditions. The Company’s product candidates utilize its programmable, biodegradable polymer-based development platform (the Precisa Platform), a delivery mechanism that seeks to enable targeted and sustained drug exposure and avoid the dose-limiting side effects associated with the current standards of care. The Company’s product candidates include EG-1962 and EG-1964. EG-1962 is a polymer-based microsphere containing nimodipine suspended in a diluent of sodium hyaluronate was developed using its Precisa development platform to improve patient outcomes following aneurysmal subarachnoid hemorrhage (aSAH).

Receive News & Ratings for Edge Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edge Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply